Abstract
The pathological process of Alzheimer's disease (AD) starts years before the appearance of clinical symptoms. The understanding of those mechanisms at the basis of such long phase will permit the development of new drugs to counter neurodegeneration before irreversible neuronal losses occur. Ideally, the development of such drugs should be based on the markers of disease progression homologous in humans and animals. The perfect experimental model recapitulating the main pathological characteristics of AD has yet to be engineered, but available models address a number of pathological AD features allowing to translate human markers to mice. The present paper is an overview of the neuroimaging markers used to map AD-like pathology and its progression in vivo in mice models of amyloidosis. Mice models are widely used to test AD candidate drugs and to predict their effects in human. Therefore, the crucial key is the identification of AD progression imaging markers homologous to those validated in early AD patients.
| Original language | English |
|---|---|
| Journal | Drug Discovery Today: Therapeutic Strategies |
| DOIs | |
| Publication status | Accepted/In press - 2013 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery
- Molecular Medicine
Cite this
A new paradigm for testing AD drugs - neuroimaging biomarkers as surrogate outcomes homologous in animals and humans. / Marizzoni, Moira; Forloni, Gianluigi; Frisoni, Giovanni B.
In: Drug Discovery Today: Therapeutic Strategies, 2013.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A new paradigm for testing AD drugs - neuroimaging biomarkers as surrogate outcomes homologous in animals and humans
AU - Marizzoni, Moira
AU - Forloni, Gianluigi
AU - Frisoni, Giovanni B.
PY - 2013
Y1 - 2013
N2 - The pathological process of Alzheimer's disease (AD) starts years before the appearance of clinical symptoms. The understanding of those mechanisms at the basis of such long phase will permit the development of new drugs to counter neurodegeneration before irreversible neuronal losses occur. Ideally, the development of such drugs should be based on the markers of disease progression homologous in humans and animals. The perfect experimental model recapitulating the main pathological characteristics of AD has yet to be engineered, but available models address a number of pathological AD features allowing to translate human markers to mice. The present paper is an overview of the neuroimaging markers used to map AD-like pathology and its progression in vivo in mice models of amyloidosis. Mice models are widely used to test AD candidate drugs and to predict their effects in human. Therefore, the crucial key is the identification of AD progression imaging markers homologous to those validated in early AD patients.
AB - The pathological process of Alzheimer's disease (AD) starts years before the appearance of clinical symptoms. The understanding of those mechanisms at the basis of such long phase will permit the development of new drugs to counter neurodegeneration before irreversible neuronal losses occur. Ideally, the development of such drugs should be based on the markers of disease progression homologous in humans and animals. The perfect experimental model recapitulating the main pathological characteristics of AD has yet to be engineered, but available models address a number of pathological AD features allowing to translate human markers to mice. The present paper is an overview of the neuroimaging markers used to map AD-like pathology and its progression in vivo in mice models of amyloidosis. Mice models are widely used to test AD candidate drugs and to predict their effects in human. Therefore, the crucial key is the identification of AD progression imaging markers homologous to those validated in early AD patients.
UR - http://www.scopus.com/inward/record.url?scp=84889022863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84889022863&partnerID=8YFLogxK
U2 - 10.1016/j.ddstr.2013.09.003
DO - 10.1016/j.ddstr.2013.09.003
M3 - Article
AN - SCOPUS:84889022863
JO - Drug Discovery Today: Therapeutic Strategies
JF - Drug Discovery Today: Therapeutic Strategies
SN - 1740-6773
ER -